胃肠道肿瘤病人血清四种因子的检测

[目的]观察胃肠道肿瘤病人血清肿瘤坏死因子α(TNFα)、可溶性白介素2受体(sIL2R)、白介素10(IL10)、白介素12(IL12)表达水平的变化.[方法]正常对照组12例,胃癌组22例,肠癌组14例,ELISA法检测各组血清TNFα、sIL2R、IL10、IL12水平.[结果]与正常对照组相比,胃癌组、肠癌组的TNFα、IL10水平均无明显变化(P>0.05),sIL2R水平均明显升高(P<0.05),胃癌组的IL12水平明显降低(P<0.001),而肠癌组的IL12水平无明显变化(P>0.05).[结论]胃癌病人血清sIL2R水平升高,IL12水平降低,肠癌病人血清sIL2R水平升高.     

肺癌患者血清PGE2水平及其对IL-2/sIL-2R的影响

目的 :探讨肺癌患者围手术期血清PGE2 水平的变化及其对IL 2 /sIL 2R的影响。方法 :采用放射免疫检测法 ( 12 5I RIA以及ELISA试剂盒 )分别检测 43例肺癌患者手术前、后的外周静脉血清PGE2 水平和IL 2 /sIL 2R ,术中抽取肿瘤回流静脉血用于检测PGE2 水平。结果 :肺癌患者外周静脉血存在较高的PGE2 ( 78 81± 3 2 15 )pg/mL ,与肿瘤回流静脉血中的PGE2 ( 13 1 0 7± 3 6 41)pg/mL呈显著相关 ,r =-0 3 15 ,P <0 0 1,术后其PGE2 显著下降 ;手术前后其IL 2 /sIL 2R处于相对较低水平 ,IL 2与PGE2 呈相关关系 ,而与sIL 2R无明显相关。术后IL 2有所上升 ( 15 3 83± 5 3 3 9)pg/mL ,但仍低于正常对照组 ( 2 3 0 2 9± 5 3 3 9)pg/mL ,P <0 0 5。结论 :肺癌患者存在着高水平的PGE2 ,是由肺部肿瘤引起的 ,对IL 2有一定的抑制作用。     

头颈癌患者T细胞亚群与白细胞介素2及其受体的动态研究

研究对35例头颈癌患者手术前后外周血T细胞亚群、IL－2及sIL－2R表达水平进行了检测，并对其中20例患者进行动态观察。结果显示：头颈癌患者CD；及sIL－2R表达显著增高，比值及IL－2水平明显低于正常人；手术后及sIL－2R表达显菩下降，比位与IL－2水平明显回升；动态观察复发者，比值及IL－2水平再显下降，及sIL－2R表达又见回升。表明：T细胞亚群与IL-2／sIL－2R的检测能反应机体抗肿瘤免疫水平，对监视病情发展、疗效观察及预后判断具有一定的临床价值，动态观察有助于监视肿瘤的复发与转移。     

胃癌病人血清IL—2R、IL—10、IL—12水平的变化

目的 观察胃癌病人血清可溶性白介素2受体（sIL-2R)、白介素10（IL－10)、白介素12（IL－12）表达水平的变化；方法 A组（正常对照组）12例，B组（胃癌带瘤组）22例，C组（胃癌术后半年内无复发组）20例，D组（胃癌术后半年以上无复发组）21例，ELISA法检测各组血清IL－2R、IL－10、IL-12水平。结果 与A组相比，B组的IL－2R水平明显升高（P＜0．005），B、C组的IL－12组的IL－12水平明显降低（P＜0．005）。与B组相比，D组的IL－2R水平明显降低（P＜0．005），IL－12水平明显回升（P＜0．05）。IL－12水平与IL－2R、IL－10水平无明显相关性。结论 胃癌病人血清IL－2R水平长高；IL－12水平降低，根除肿瘤后IL－2R、IL－12逐渐恢复正常。     

肝癌患者外周血IL—2R检测及其意义

白细胞介素Ⅱ(IL—2)及白细胞介素Ⅱ受体(IL—2R)在人类免疫应答中起着重要作用。IL—2R包括膜表面受体(mIL—2R)及可落性受体(sIL—2R)二种类型。本文对肝癌患者外周血T细胞mIL—2R表达及血清sIL—2R含量进行研究,现将结果报道如下。     

恶性肿瘤患者血清sIL-2R与TNF的表达及临床意义研究

采用ELlSA夹心法和~3H—TdR释放法分别对217例恶性肿瘤病人血清sIL—2R和TN0进行测定,结果发现,恶性肿瘤患者血清sIL—2R和TNF均明显高于正常对照(p<0.001),并与临床分期,肿瘤进展,以及病情的严重程度有关;伴有转移的患者血清sIL-2R和TNF升高幅度更为明显,与病情稳定或非转移患者相比有显著性差异(p<0.001)。所以,检测恶性肿瘤患者血清sIL-2R和TNF不但能了解癌症患者机体的免疫状态,且能在一定程度上对疾病的严重程度、肿瘤分期、进展、转移、疗效及预后等作出评估。     

薏苡仁提取物注射液对晚期原发性肝癌患者免疫功能影响的研究

目的 :探讨薏苡仁提取物 (康莱特 ,KLT)注射液对晚期原发性肝癌 (PHC)患者免疫功能的影响。方法 :用KLT治疗晚期PHC 52例为治疗组 ,并以常规对症处理治疗 4 2例晚期PHC为对照组。检测两组患者治疗前后外周血T淋巴细胞亚群 (T LS)及血清可溶性白细胞介素 2受体 (sIL 2R)水平。结果 :治疗组患者外周血CD3 细胞、CD4 细胞、CD4 /CD8 细胞比值治疗后较治疗前明显增高 (P均 <0 .0 5) ,CD8 细胞无显著性改变 (P >0 .0 5) ,血清sIL 2R明显降低 (P <0 .0 5) ;而对照组患者治疗后外周血CD3 细胞、CD4 细胞、CD4 /CD8 细胞比值及sIL 2R较治疗前无显著性改变 (P均 >0 .0 5)。结论 :KLT对晚期PHC患者的免疫功能有一定改善作用     

血清sIL-2R和CA125水平对卵巢恶性肿瘤临床诊断意义的探讨

 分别采用ELISA和RIA对36例卵巢恶性肿瘤、34例妇科良性肿瘤患者及31例正常女性献血员血清可溶性白细胞介素-2受体(sIL－2R)和CA125水平进行检测。结果:术前卵巢恶性肿瘤患者血清SIL－2R和CA125水平均明显高于良性及正常对照组(P<0.01)。血清sIL－2R检测恶性肿瘤的敏感性为77.8％,特异性为76.5％。血清CA125的敏感性为83.3％,特异性为73.5％。其中,对卵巢上皮癌敏感性为90.4％。联合检测卵巢恶性肿瘤患者血清sIL－2R和CA125的敏感性为57.4％,特异性为94.7％。提示:术前单项血清sIL－2R或CA125不能作为诊断和筛选卵巢恶性肿瘤的依据,联合检测血清sIL－2R或CA125可明显提高特异性,降低假阳性率,有助于临床手术方式的制定和以后治疗成功的可能性。     

乳腺癌患者血清sIL-2R水平的动态研究

目的 :探讨乳腺癌血清可溶性白细胞介素 2受体 (solubleinterleukin 2receptor ,sIL 2R)水平的动态变化。方法 :采用ELISA法检测 52例手术前后乳腺癌患者、32例乳腺良性疾病患者及 33例正常人血清sIL 2R水平。结果 :乳腺癌患者血清sIL 2R明显高于乳腺良性疾病组和正常对照组 ,其手术后3周血清sIL 2R水平明显低于术前 ;乳腺癌患者血清sIL 2R水平与临床分期密切相关 ,Ⅲ期患者血清sIL 2R水平明显高于Ⅰ、Ⅱ期。结论 :血清sIL 2R的表达水平可作为乳腺癌的一项标志物。     

大肠癌患者血清癌胚抗原、可溶性 Fas、白细胞 介素 -6水平测定及其临床意义

目的探讨大肠癌患者血清癌胚抗原（carcinoembryonic antigen,CEA）、可溶性Fas(solubleFas,sFas)、白细胞介素-6(interleukin-6,IL-6)水平的临床意义。方法采用双抗体夹心ELISA方法检测162例大肠癌患者术前、术后血清中sFas、IL-6表达水平,同时测定了相关免疫指标及血清CEA水平。结果大肠癌患者血清sFas水平为（20.97±8.19）ng/L,阳性率为53.70％;IL-6水平为（36.87±11.20）ng/L,阳性率67.91％;CEA水平为（32.52±10.81）μg/L,阳性率41.98％,三者均非常显著高于良性病变及对照组。大肠癌患者术前血清CEA、sFas、IL-6水平均显著高于术后（P<0.01),以sFas、IL6水平升高更明显。血清sFas水平与癌转移相关,而血清IL6与肿瘤大小及癌转移明显相关（P<0.01)。仅血清sFas水平与淋巴细胞转化率、LAK及NK活性呈显著负相关。CEA、IL6、sFas三者之间均呈显著正相关。结论大肠癌患者血清sFas、IL6检测阳性率高于CEA。sFas、IL6反映了肿瘤的增殖和转移情况,这可能与sFas抑制了免疫功能和肿瘤细胞的凋亡有关;IL6有促进肠癌细胞的增殖作用。三者联合检测对大肠癌患者的临床诊断、判断预后及监测疗效有重要作用。     

Expression of sIL-2R before and after chemotherapy in patients with breast cancer

Objective:To investigate the difference of peripheral blood sIL-2R before and after chemotherapy in breast cancer patients,and evaluate the clinical value of the sIL-2R in breast cancer's diagnosis and therapy.Methods:The peripheral blood sIL-2R levels of the breast cancer patients with or without chemotherapy were detected by ELISA.The healthy persons were made as the control group.Results:The slL-2R levels of the breast cancer patients were higher than that of the control group(P＜0.05);the slL-2R's levels in Ⅰ～Ⅱ stage breast cancer were lower than that in Ⅲ～Ⅳ stag e breast cancer (P＜0.05);the sIL-2R levels of the patients before chemotherapy were higher than that of the patients undergone chemotherapy(P＜0.05);The level of the patient with chemotherapy was still higher than that of the control group(P＜0.05);the sIL-2R levels of the patients whose chemotherapies were noneffective were higher than that of the patients received effective chemotherapies(P＜0.05).There was no significant difference between the group with ER( )or PR( )and the group with ER(-)or PR(-)(P＞0.05).Conclusion:The breast cancer patients have the high slL-2R levels.There is a close relationship between the cancer incidence and the patients,immune situation.The level of slL-2R could be a clinical index which Can be used for evaluating the cancer degree,because the higher levels of slL-2R can indicate that the immune ability of patient is worse.There is a significant difference between the slL-2R levels of the patients before chemotherapy and that of the patients undergone chemotherapy.     

Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer

Background: In the present study, we investigated the significance of serum soluble interleukin-2 receptor (IL-2R) as a tumor marker, and examined the existence and localization of cells positive for IL-2R/Tac antigen in colorectal cancer tissues and their regional lymph nodes. Methods: The study included 155 patients with colorectal cancer. Levels of serum soluble IL-2R were measured by an enzyme-linked immunosorbent assay. In the tissues obtained from 18 patients, immunohistochemical staining was performed, with the use of the avidin-biotin-peroxidase complex technique, in which mouse anti-human IL-2R antibody was used. Results: The preoperative levels of serum soluble IL-2R in patients with colorectal cancer were significantly higher than those of normal controls (P = 0.0065). The levels of serum soluble IL-2R in patients with metastatic lymph nodes were also significantly higher than the levels in those without metastatic lymph nodes (P = 0.0258). Concerning tumor markers, there were significant differences in serum soluble IL-2R levels between patients who were positive and those who were negative for carcinoembryonic antigen (CEA) and between these who were positive and those who were negative for immunosuppressive acidic protein (IAP). In the immunohistochemical staining of IL-2R, 16 of the 18 patients (88.8%) showed IL-2R-positive cells in the colorectal cancer tissues. In regard to the metastatic lymph nodes, all of 5 patients (100%) showed IL-2R-positive cells. On the other hand, IL-2R-positive cells were not recognized in normal colorectal tissues and non-metastatic lymph nodes. Conclusion: These results suggest that activated T lymphocytes infiltrating into cancer tissues to play an antitumor role may release a large amount of the α-chain of IL-2R, resulting in the high levels of serum soluble IL-2R in patients with colorectal cancer. Received: October 18, 2001 / Accepted: June 12, 2002 Acknowledgments This study was supported in part by a Grant-in Aid for Scientific Research (11671269) from the Japanese Ministry of Education, Science, and Culture. Correspondence to:S. Murakami     

Serum Soluble Interleukin-2 Receptor in Colorectal Cancer

Preoperative serum soluble interleukin-2 receptor (IL-2R) levels were measured in patients with colorectal cancer, and correlated with various factors as stage, lymph node metastasis, liver metastasis, grade, serum CEA and IAP (immunosuppressive acidic protein). The levels of serum soluble IL-2R in Dukes stage C were significantly higher than in normal control and in Dukes stage A. Serum levels were also significantly higher in patients with lymph node metastasis than in patients without such metastasis, and in IAP positive patients compared to IAP negative patients. Preoperative serum IL-2R levels thus seem to reflect the stage of the disease.     

大肠癌患者血清和组织中sIL-2R和sICAM-1水平的变化及意义

目的研究大肠癌血清和组织中sIL-2R和sICAM-1水平变化及意义。方法采用双抗体夹心ELISA法对44例大肠癌手术前后、28例大肠息肉、30例对照组血清sIL-2R和sICAM-1水平进行检测,并检测大肠癌及大肠息肉组织中两者水平。结果大肠癌组血清sIL-2R、sICAM-1水平分别为（209．27±127．42）pmol／L、（693．22±276．25）ng／ml,明显高于大肠息肉组和对照组。大肠癌组织中两者水平分别为（233．66±170．22）pmol／L、（706．92±286．09）ng／ml,明显高于大肠息肉组。大肠癌血清和组织中两者水平与Duke分期有关,与组织分化程度无关。大肠癌根治性手术后1个月血清两者水平明显下降,而姑息性手术下降不明显。结论血清和肿瘤组织中sIL-2R、sICAM-1水平变化可作为大肠癌诊断、手术方法选择、预后监测有意义的参考指标。     

Significance of Increased Neutrophils in Patients with Advanced Colorectal Cancer

We examined the ratio of neutrophils to lymphocytes (N/L ratio) in the peripheral blood in patients with colorectal cancer. The ability to produce active oxygen and phagocytosis of neutrophils, G-CSF, sIL-2R and IAP (immunosuppressive acidic protein) were also measured. The N/L ratios were significantly higher in the advanced stages of cancer than in normal controls. The ability to produce active oxygen in the terminal stage was 33% lower than in the control group. The G-CSF levels had no relationship with the neutrophil counts. IAP levels increased with cancer stage, and were inversely related to the ability to produce active oxygen. The IAP levels correlated well with the sIL-2R levels and the N/L ratio. These findings suggest that the ability to produce active oxygen, N/L ratio and IAP reflect anticancer mechanisms and that they may be useful when considering treatment or prognosis of patients with advanced stages of cancer.     

肝细胞癌患者血清IL—6,IL—2系统的变化及相互关系

目的：研究肝细胞癌患者ＩＬ－６、ＩＬ－２、ｓＩＬ－２Ｒ的变化和意义。方法：分别采用ＡＢＳ－ＥＬＩＳＡ法、双抗体夹心ＥＬＩＳＡ法对４０例肝癌患者进行了ＩＬ－６、ＩＬ－２、ｓＩＬ－２Ｒ的测定,并与２６例肝地硬化和６６例健康献血员进行了对照。结果：肝细胞癌（ＨＣＣ）患者血清ＩＬ－６、ｓＩＬ－２Ｒ水平明显升高,而ＩＬ－２水平明显低于正常对照（ＮＣ）组（Ｐ〈０．０１）,ＨＣＣ组的ＩＬ－６水平高出正常１０倍以     

大肠癌血清肿瘤坏死因子α、白细胞介素8和可溶性白细胞介素2受体水平的检测及其临床意义

目的探讨血清肿瘤坏死因子（TNFα）、白细胞介素8（IL-8）和可溶性白细胞介素2受体（sIL-2R）水平在结直肠癌中的意义。方法用酶联免疫吸附试验（ELISA）法测定93例结直肠癌患者和33例健康对照组外周静脉血清TNFα、IL-8和sIL-2R含量。结果结直肠癌患者血清TNFα、IL-8和sIL-2R含量明显高于正常对照组（P〈0．001）,Dukes分期C＋D期结肠癌患者血清TNFα,IL-8和sIL-2R含量明显高于DukesA＋B期（P〈0．001）,手术后3年复发者血清TNFα、IL-8和sIL-2R的含量均高于未复发组（P〈0．001）。结论TNFα、IL-8、sIL-2R是与结肠癌病情变化和预后相关的细胞因子,可作为结肠癌病情监测和预后判断的指标。     

Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer

Background:

Interleukin-6 (IL-6) binds both the membrane and soluble forms of the IL-6 receptor (sIL-6R), which induces a complex with gp130, and proliferation of tumour cells. The aim of this study is to clarify the relationship between tumoral sIL-6R expression and disease progression in colorectal cancer patients.

Methods:

We measured tissue concentrations of sIL-6R in tumour and normal mucosa from 161 colorectal cancer patients undergoing surgery, and in supernatants from colon cancer cell lines. The expression of IL-6, IL-6R and gp130 was evaluated by immunohistochemical analysis.

Results:

Loss of tumour expression of sIL-6R as defined by sIL-6R Ca/N ratio <1.0 was significantly associated with factors reflecting disease progression, and was an independent prognostic factor not only in all the patients in this study, but also in the patients with curative intent. Colon cancer cell lines produced sIL-6R in vitro, and the production of sIL-6R in cancer cell lines was stimulated by cytokine stimulation. Immunohistochemistry revealed that loss of tumour expression of sIL-6R was significantly inversely correlated with intense IL-6 expression in the cytoplasm of cancer cells. In addition, tumoral IL-1β expression was significantly correlated with sIL-6R expression.

Conclusion:

Loss of tumour expression of sIL-6R is associated with colorectal cancer disease progression.     

血清白细胞介素18在前列腺癌患者中的临床价值

Objective: To determine serum interleukin-18 (IL-18) levels and their clinical significance in patients with prostate cancer. Methods: Peripheral blood samples were obtained from 38 nonmetastatic and 18 metastatic prostate cancer patients who underwent curative surgery and from 25 healthy volunteers. The serum IL-18 level was determined in each sample with the enzyme-linked immunosorbent assay. Results: The levels of serum IL-18 were increased significantly in prostate cancer patients compared with control subjects (P ＜ 0.05). Serum IL-18 levels were significantly higher in the metastatic patients compared with the nonmetastatic patients (P ＜ 0.01). Patients with bone metastasis had higher serum IL-18 levels compared with patients with liver and lung metastasis (P ＜ 0.01). When the patients were subdivided into groups, it was found that the serum IL-18 levels in patients with T2, T3 and T4 stage were significantly higher than that of T1 stage patients (P ＜ 0.01). Patients with IL-18 levels ≥ 316 pg/mL experienced a significantly lower survival rate compared with the patients who had IL-18levels ＜ 316 pg/mL after undergoing surgery (P ＜ 0.05). The serum IL-18 level was identified as an independent postoperative prognostic factor in multivariate survival analysis using a Cox proportional hazards model (hazard ratio, 4.21; P = 0.02).Conclusion: The serum IL-18 level may be a useful marker in monitoring prostate cancer patients. IL-18 activity in prostate cancer patients with bone metastasis may be more valuable in the follow-up.     

Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells

Soluble interleukin-2 receptor (sIL-2R) α (CD25) levels were serially determined in the sera of 20 patients who had undergone adoptive immunotherapy with high-dose IL-2 and lymphokine-activated killer (LAK) cells for various types of metastatic solid tumors or Hodgkin’s disease. The treatment course consisted of 5 days of high-dose IL-2 priming followed by the collection of peripheral blood leukocytes by leukapheresis, andin vitro activation of mononuclear cells with IL-2, and the subsequent infusion of such prepared LAK-cells together with IL-2. sIL-2R levels increased in all patients following IL-2 administration, and the ratio of baseline sIL-2R levels to those measured after 5 days of IL-2 was signifıcantly correlated with pre-IL-2 levels (p=0.016) in that higher pre-IL-2 levels resulted in a larger increase upon IL-2 administration. In terms of treatment outcome, the variables analysed included sIL-2R levels, total IL-2 doses administered, the expression of membrane-bound CD25 onin vitro cultured cells (pre- and post-IL-2 exposure), the total number of LAK-cells infused andin vitro cytotoxic activity of LAK-cells against the natural killer cell-resistant cell line Daudi. In a multivariate analysis, low baseline sIL-2R levels (p=0.095) and highin vitro cytotoxic activity of LAK-cells against Daudi cells (p=0.082) were jointly associated with response. Our data suggest that serum sIL-2R levels provide a fast and non-invasive parameter for predicting the response in patients treated with IL-2 and LAK-cells.